Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NiproNPRRF 72 6-1 Month Momentum % is 21.02% as of Aug. 05, 2026. GuruFocus rates NPRRF with a GF Score™ of 72/100 and a GF Value™ of $9.30. The stock has 6 warning signs investors should review. Among 844 Medical Devices & Instruments companies, Nipro ranks better than 79.27% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-05), Nipro's 6-1 Month Momentum % is 21.02%.
The industry rank for Nipro's 6-1 Month Momentum % or its related term are showing as below:
NPRRF's 6-1 Month Momentum % is ranked better than 79.27% of 844
companies
in the Medical Devices & Instruments industry
Industry Median: -11.41
vs NPRRF: 21.02
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Nipro 6-1 Month Momentum % Related Terms
NPRRF vs ISRG, BDX, MDLN: 6-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Nipro's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro 6-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Nipro's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro (NPRRF) has a 6-1 Month Momentum % of 21.02% as of Aug. 05, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Nipro and its competitors. According to the industry distribution chart, Nipro ranks #175 out of 844 companies in the Medical Devices & Instruments industry, placing it in the top 20.7%.
Is Nipro's 6-1 Month Momentum % too high?
Nipro's current 6-1 Month Momentum % is 21.02%. Based on the distribution chart, Nipro ranks #175 out of 844 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nipro has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Nipro's 6-1 Month Momentum % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nipro ranks #175 out of 844 companies for 6-1 Month Momentum %. This places Nipro in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Medical Devices & Instruments company?
A good 6-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Nipro and its competitors. Nipro's current 6-1 Month Momentum % is 21.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Nipro (NPRRF) has a current 6-1 Month Momentum % of 21.02%. The stock's GF Value™ is $9.30, compared to a current price of $9.96 — trading 7.1% above its estimated fair value. The current 6-1 Month Momentum % is 21.02%. Nipro's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Nipro (NPRRF), the current 6-1 Month Momentum % is 21.02% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (NPRRF) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be overvalued.
The current stock price of $9.96 is trading 7.1% above its estimated GF Value™ of $9.30.
Key valuation signals for NPRRF:
6-1 Month Momentum %: 21.02%
GF Value™: $9.30 vs. price of $9.96 (7.1% above fair value)
No single metric tells the full story. See the NPRRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
72GF Score
Get the complete analysis for NPRRF
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPRRF has been successfully added to your 
